Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
HIV patients treated with antiretroviral therapy (ART) often develop increased visceral adipose tissue (VAT).
Our objective was to perform a pooled analysis of two phase-3 studies of tesamorelin in ART-treated HIV patients with excess abdominal fat.
DESIGN AND SETTING
Two multicenter, international studies were conducted; a 26-wk… (More)